More specifically, studies have shown that the CX3CL1/CX3CR1 axis is overexpressed in invading glioma cells, and when treated with neutralizing antibodies, this invasiveness is largely reduced [41]. This evidence concerns the gene CX3CR1 and central nervous system cancer.